Edgar Filing: KAILIAN VAUGHN M - Form 3

KAILIAN VAUGHN M

Form 3 May 30, 2013

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

MPM BioVentures IV QP LP

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

05/30/2013

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Epizyme, Inc. [EPZM]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O MPM ASSET MANAGEMENT, 200 **CLAREDON STREET, 54TH FLOOR**

(Street)

(State)

(Check all applicable)

X 10% Owner Director Officer Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person

X Form filed by More than One

Reporting Person

BOSTON, MAÂ 02116

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

(City)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect

(Instr. 5)

Common Stock Ι 178,331 (1) See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not

required to respond unless the form displays a

currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security**

Conversion Ownership

6. Nature of Indirect Beneficial Ownership

or Exercise Form of (Instr. 5)

Edgar Filing: KAILIAN VAUGHN M - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	(3)	(3)	Common Stock	2,309,998	\$ <u>(3)</u>	I	See Footnote (4)
Series B Preferred Stock	(5)	(5)	Common	392,156	\$ <u>(5)</u>	I	See Footnote (6)

Reporting Owners

Reporting Owner Name / Address		Relationships				
reporting 6 wher reduces	Director	10% Owner	Officer	Other		
MPM BioVentures IV QP LP C/O MPM ASSET MANAGEMENT 200 CLAREDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
Scopa James Paul C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO, CA 94080	Â	ÂX	Â	Â		
Vander Vort John C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
MPM Asset Management Investors BV4 LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
MPM BioVentures IV GmbH & Co. Beteiligungs KG C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
MPM BioVentures IV GP LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
MPM BioVentures IV Strategic Fund, L.P. C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116	Â	ÂX	Â	Â		
MPM BioVentures IV LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR	Â	ÂX	Â	Â		

Reporting Owners 2

Â

ÂXÂ

Â

BOSTON, MAÂ 02116

Foley Todd

C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR Â Â X Â Â

BOSTON, MAÂ 02116

KAILIAN VAUGHN M

C/O MPM ASSET MANAGEMENT

200 CLARENDON STREET, 54TH FLOOR

BOSTON, MAÂ 02116

Signatures

By Luke Evnin, member of MPM BioVentures IV LLC, the managing member of MPM				
BioVentures IV GP LLC, the general partner of MPM BioVentures IV-QP, L.P. /s/ Luke Evnin				
**	*Signature of Reporting Person	Date		
/s/ James P. Scopa		05/30/2013		
***	*Signature of Reporting Person	Date		
/s/ John Vander Vort		05/30/2013		
**	*Signature of Reporting Person	Date		
By Luke Evnin, member of MPM Bio Management Investors BV4 LLC /s/	05/30/2013			
***	*Signature of Reporting Person	Date		
	oVentures IV LLC, the managing member of MPM ing limited partner of MPM BioVentures IV GmbH & Co.	05/30/2013		
**	*Signature of Reporting Person	Date		
By Luke Evnin, member of MPM Bio BioVentures IV GP LLC /s/ Luke Ev	05/30/2013			
***	*Signature of Reporting Person	Date		
•	oVentures IV LLC, the managing member of MPM l partner of MPM BioVentures IV Strategic Fund, L.P. /s/	05/30/2013		
**	*Signature of Reporting Person	Date		
By Luke Evnin, member of MPM Bio	05/30/2013			
***	*Signature of Reporting Person	Date		
/s/ Todd Foley		05/30/2013		
***	*Signature of Reporting Person	Date		
/s/ Vaughn Kailian		05/30/2013		
**	*Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects a one-for-three reverse stock split effected May 13, 2013.

Signatures 3

Edgar Filing: KAILIAN VAUGHN M - Form 3

- The shares are held as follows: 166,007 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 6,395 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG"), 4,720 by MPM Asset Management Investors BV4 LLC ("AM BV4") and 1,209 shares held by MPM BioVentures IV Strategic Fund, L.P. ("BV IV SF"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the
- direct and indirect general partners of BV IV QP, BV IV KG and BV IV SF and BV LLC is the manager of AM BV4. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa, Todd Foley and John Vander Vort are the members of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- Each share of Series A Preferred Stock is convertible into 1/3rd of a share of Common Stock without payment of further consideration and will automatically convert into 1/3rd of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- The shares are held as follows: 1,850,799 by BV IV QP, 71,303 by BV IV KG, 52,628 by AM BV4 and 335,268 shares held by BV IV (4) SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein
- Each share of Series B Preferred Stock is convertible into 1/3rd of a share of Common Stock without payment of further consideration and will automatically convert into 1/3rd of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- The shares are held as follows: 312,152 by BV IV QP, 12,026 by BV IV KG, 8,876 by AM BV4 and 59,102 shares held by BV IV SF.

 (6) Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Â

Remarks:

See Form 3 for Luke Evnin for additional members of this joint filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.